Payment overview · 2025
General Payments
$905.01
52 reported records · 18 companies
Healthcare provider profile · identity verified
Walter Walthall, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1750460317
Verified facts
What the public records show
CMS Open Payments records show Walter Walthall, MD received $905.01 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.80 | 19.6% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $168.95 | 18.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.48 | 11.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.63 | 7.6% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $63.38 | 7.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.14 | 5.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.20 | 3.8% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $32.19 | 3.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.03 | 3.5% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $28.96 | 3.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.84 | 2.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.49 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.22 | 2.0% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $18.00 | 2.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.41 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.36 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.07 | 1.7% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $13.86 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $905.01 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.56 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.52 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $85.34 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.60 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $63.38 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.24 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.14 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.14 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.39 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $32.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.03 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.52 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.52 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.52 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $26.15 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 506 | 150 |
| Losartan Potassium | Losartan Potassium | 398 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 98 |
| Lisinopril | Lisinopril | 279 | 86 |
| Metformin Hcl | Metformin Hcl | 253 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 54 |
| Gabapentin | Gabapentin | 180 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 57 |
| Omeprazole | Omeprazole | 152 | 46 |
| Trazodone Hcl | Trazodone Hcl | 145 | 46 |
| Simvastatin | Simvastatin | 143 | 41 |
| Bupropion Xl | Bupropion Hcl | 127 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 34 |
| Ozempic | Semaglutide | 109 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 36 |
| Celecoxib | Celecoxib | 103 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 33 |
| Tramadol Hcl | Tramadol Hcl | 103 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 25 |
| Memantine Hcl | Memantine Hcl | 98 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 23 |
| Metformin Hcl Er | Metformin Hcl | 90 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 27 |
| Montelukast Sodium | Montelukast Sodium | 86 | 25 |
| Alprazolam | Alprazolam | 84 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 27 |
| Carvedilol | Carvedilol | 75 | 22 |
| Alendronate Sodium | Alendronate Sodium | 71 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 20 |
| Finasteride | Finasteride | 69 | 21 |
| Azithromycin | Azithromycin | 67 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 17 |
| Allopurinol | Allopurinol | 63 | 19 |
| Chlorthalidone | Chlorthalidone | 61 | 19 |
| Furosemide | Furosemide | 61 | 29 |
| Meloxicam | Meloxicam | 61 | 21 |
| Prednisone | Prednisone | 61 | 47 |
| Pregabalin | Pregabalin | 60 | 14 |
| Cephalexin | Cephalexin | 58 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 20 |
| Donepezil Hcl | Donepezil Hcl | 56 | 19 |
| Potassium Chloride | Potassium Chloride | 55 | 25 |
| Azelastine Hcl | Azelastine Hcl | 54 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Eliquis | Apixaban | 52 | 13 |
| Sertraline Hcl | Sertraline Hcl | 50 | 19 |
| Glipizide | Glipizide | 48 | 11 |
| Atenolol | Atenolol | 46 | 14 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 11 |
| Cefdinir | Cefdinir | 44 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | 11 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Famotidine | Famotidine | 34 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 16 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 19 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Estradiol | Estradiol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Temazepam | Temazepam | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Zolmitriptan | Zolmitriptan | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $905.01 · 52 records | ABBVIE INC. | ABRYSVO, AJOVY, AREXVY, Azstarys, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Fluad, Flucelvax, KRYSTEXXA, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PANCREAZE, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error